Maternal Methylenetetrahydrofolate Reductase C677T
Polymorphism and Down Syndrome Risk: A MetaAnalysis from 34 Studies
Vandana Rai1*, Upendra Yadav1, Pradeep Kumar1, Sushil Kumar Yadav1, Om Prakesh Mishra2
1 Human Molecular Genetics Laboratory, Department of Biotechnology, VBS Purvanchal University, Jaunpur, India, 2 Department of Pediatrics, Institute of Medical
Sciences, Banaras Hindu University, Varanasi, India
Abstract
Background: Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme of folate metabolic pathway which catalyzes
the irreversible conversion of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. 5-methyltetrahydrofolate
donates methyl group for the methylation of homocysteine to methionine. Several studies have investigated maternal
MTHFR C677T polymorphism as a risk factor for DS, but the results were controversial and inconclusive. To come into a
conclusive estimate, authors performed a meta-analysis.
Aim: A meta-analysis of published case control studies was performed to investigate the association between maternal
MTHFR C677T polymorphism and Down syndrome.
Methods: PubMed, Google Scholar, Elsevier, Springer Link databases were searched to select the eligible case control
studies using appropriate keywords. The pooled odds ratio (OR) with 95%confidence interval were calculated for risk
assessment.
Results: Thirty four studies with 3,098 DS case mothers and 4,852 control mothers were included in the present metaanalysis. The pooled OR was estimated under five genetic models and significant association was found between maternal
MTHFR 677C.T polymorphism and Down syndrome under four genetic models except recessive model (for T vs. C,
OR = 1.26, 95% CI = 1.09–1.46, p = 0.001; for TT vs. CC, OR = 1.49, 95% CI = 1.13–1.97, p = 0.008; for CT vs. CC, OR = 1.29, 95%
CI = 1.10–1.51, p = 0.001; for TT+CT vs. CC, OR = 1.35, 95% CI = 1.13–1.60, p = 0.0008; for TT vs. CT+CC, OR = 0.76, 95%
CI = 0.60–0.94, p = 0.01).
Conclusion: The results of the present meta-analysis support that maternal MTHFR C677T polymorphism is a risk factor for
DS- affected pregnancy.
Citation: Rai V, Yadav U, Kumar P, Yadav SK, Mishra OP (2014) Maternal Methylenetetrahydrofolate Reductase C677T Polymorphism and Down Syndrome Risk: A
Meta-Analysis from 34 Studies. PLoS ONE 9(9): e108552. doi:10.1371/journal.pone.0108552
Editor: Balraj Mittal, Sanjay Gandhi Medical Institute, India
Received April 26, 2014; Accepted August 28, 2014; Published September 29, 2014
Copyright: ß 2014 Rai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* Email: raivandana@rediffmail.com
reductase (MTRR) in Asian [1,2,4,5] and Caucasian [6–8]
populations. Folate deficiency and dysfunctional MTHFR causes
abnormal DNA methylation [9,10] and chromosomal segregation
[11,12]. Hypomethylation of the centromeric DNA has been
suggested as the causative mechanism of meiotic non-disjunction.
Abnormal DNA methylation of centromere lead to aberrant
kinetochore formation that results into abnormal segregation of
chromosomes during meiosis [3,13].
MTHFR is a key enzyme in folate metabolism, which catalyzes
the reduction of 5, 10-methylenetetrahydrofolate to the predominant circulating form of folate i.e. 5-methyltetrahydrofolate (5THF). 5-THF donates methyl group for the conversion of
homocysteine to methionine, which is further converted into Sadenosylmethionine (SAM). SAM is the main methyl group donor
for all cellular methylation reactions. Folate deficiency and/or
dysfunctional MTHFR reduces the conversion of 5, 10-methylene
THF to 5-methyl THF, and elevates plasma homocysteine
Introduction
Down syndrome (DS) is the most common chromosomal
disorder with the prevalence of 1/700–1000 live birth. It is
characterized by the trisomy 21, which results from maternal
meiotic nondisjunction in majority (90%) of cases. The established
risk factor for DS is advanced (.35 years) maternal age at the time
of conception. However, a fairly high number of DS children born
to younger mothers suggest that risk factors other than advanced
maternal age might be involved in predisposing younger mothers
to DS-affected pregnancy [1,2]. The molecular and biochemical
mechanism of maternal meiotic non-disjunction is still not known.
James et al. [3] reported that methylenetetrahydrofolate reductase
(MTHFR) C677T polymorphism might be a risk factor for
maternal meiotic non-disjunction. Since then several studies have
investigated the risk of DS to variants of folate pathway genes like
MTHFR, Methionine synthase (MTR) and Methionine synthase
PLOS ONE | www.plosone.org
1
September 2014 | Volume 9 | Issue 9 | e108552
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
Figure 1. Flow Diagram of Study Searching and Selection Process.
doi:10.1371/journal.pone.0108552.g001
conflicting and inconclusive. In light of the above facts, we
conducted a meta-analysis of published case control studies
relating the C677T polymorphism of the maternal MTHFR gene
to the risk of having DS offspring.
concentration. Both folate and MTHFR are involved in many
complex biochemical reactions like DNA synthesis, repair and
methylation.
There are more than 40 polymorphisms reported in MTHFR
gene and among them C677T variant is the most studied and
clinically important. The C677T variant (rs 1801133; Ala 222 Val)
has been associated with a decreased activity of MTHFR, and
increased homocysteine level [14–16]. Mutant homozygous (TT)
individuals have a decreased enzymatic activity , 70% and the
heterozygote by 40%. A dysfunctional MTHFR leads to lower
levels of SAM resulting into DNA hypomethylation. DNA
hypomethylation increases the risk of many diseases and disorders
like- neural tube defects [17], cleft lip and palate [18], Alzheimer
disease [19], cardiovascular diseases [14], diabetes [20] and
psychiatric disorders [21] etc. Several epidemiological studies have
investigated the associations of the maternal MTHFR C677T
polymorphism with Down syndrome. However, the results were
PLOS ONE | www.plosone.org
Materials and Methods
Selection of studies
Electronic searches were conducted using PubMed, Google
Scholar, Elsevier and Springer link and all published manuscripts
up to January, 2014 were considered in present meta-analysis. The
following index terms were used for search ‘MTHFR’ ‘Methylenetetrahydrofolate reductase’, and ‘C677T polymorphism’, ‘maternal risk’ and ‘Down syndrome’. In addition, bibliographies of all
articles and reviews were hand searched for additional suitable
studies.
2
September 2014 | Volume 9 | Issue 9 | e108552
PLOS ONE | www.plosone.org
Table 1. Characteristics of the eligible studies included in the meta-analysis.
Study
Year
Country
Case
Control
Quality Score
Reference
James et al.
1999
Canada
50
57
7
Am J Clin Nutr 70:495-50
Hobbs et al.
2000
America
157
140
7
Am J Hum Genet 67:623–630
Chadeaux-Vekemans et al.
2002
France
85
70
5
Pediatr Res 51:766–767
O’Leary et al.
2002
Ireland
41
192
5
Am J Med Genet A 107:151–155
Stuppia et al.
2002
Italy
64
112
7
Eur J Hum Genet 10:388–390
Boduroglu et al.
2004
Turkey
158
91
5
Am J Med Genet 127A: 5–10
Acacio et al.
2005
Brazil
70
88
8
Prenat Diagn 25:1196–1199
Da Silva et al.
2005
Brazil
154
158
7
Am J Med Genet Part A 135A: 263–267
Coppede et al.
2006
Italey
79
111
7
Am J Med Genet A 140(10): 1083–1091
Liang et al.
2006
China
30
70
7
China J Modern Medicine 20:011
Rai et al.
2006
India
149
165
6
J Hum Genet 51:278–283
Scala et al.
2006
Italy
94
256
8
Genet Med 8:409–416
Wang et al.
2007
China
100
100
8
Zhonghua Yi Xue Yi Chuan Xue Za Zhi 24:533–537
Biselli et al.
2008
Brazil
82
134
8
Genet Mol Res 7:33–42
3
Kohli et al.
2008
India
103
109
6
Downs Syndr Res Pract 12:133–137
Martinez-Frias et al.
2008
Spain
146
188
4
Am J Med Genet A 146A(11): 1477–1482
Meguid et al.
2008
Egypt
42
48
7
Dis Markers 24:19–26
Santos-Reboucas et al.
2008
Brazil
103
108
7
Dis Markers 25:149–157
2008
China
64
70
8
J Zhejiang Univ Sci B 9(2): 93–99
Brandalize et al.
2009
Brazil
239
197
6
Am J Med Genet 149A (10): 2080–2087
Coppede et al.
2009
Italy
94
113
8
Neurosci Lett 449:15–19
September 2014 | Volume 9 | Issue 9 | e108552
Cyril et al.
2009
India
36
60
6
Indian J Hum Genet 15:60–64
Kokotas et al.
2009
Denmark
177
984
6
Dis Markers 27:279–285
Pozzi et al.
2009
Italy
74
184
8
Am J Obstet Gynecol 63: e1–e6
Coppede et al.
2010
Italy
29
32
5
BMC Med Genomics 3:42
Liao et al.
2010
China
60
68
7
Yi Chuan 32(5): 461–466
Vranekoviz et al.
2010
Croatia
111
141
7
Dis Markers 28:293–298
Bozovic et al.
2011
Croatia
112
221
7
Pediatr Int 53(4): 546–550
Sadiq et al.
2012
Jordan
53
29
6
Genet Test Mol Biomarker 15:1–7
Tayeb
2012
Saudi Arabia
30
40
5
Egyptian J Med Hum Genet 13(3): 263–268
Zampieri et al.
2012
Brazil
105
185
8
Dis Markers 32(2): 73–81
Kaur and Kaur
2013
India
110
111
6
Indian J Hum Genet 19(4): 412–414
Pandey et al.
2013
India
81
99
6
Int J Pharm Bio Sci; 4(2):(B)249–256
Elsayed et al.
2014
Egypt
26
61
9
The Egyptian J Med Hum Genet 15(1): 39–44
doi:10.1371/journal.pone.0108552.t001
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
Wang et al.
PLOS ONE | www.plosone.org
Table 2. Distributions of MTHFR C677T genotypes and allele frequencies in DS case mothers and control mothers reported in different included studies.
CC
CT
TT
C
T
Study
Country
Case
Control
Case
Control
Case
Control
Case
Control
Case
Control
James et al., 1999
Canada
24
15
22
34
4
8
70
64
30
50
Hobbs et al., 2000
America
51
67
84
59
22
14
186
193
128
87
Chadeaux-Vekemans et al., 2002
France
36
29
42
30
7
11
114
88
56
52
O’Leary et al., 2002
Ireland
18
90
21
84
2
18
57
264
25
120
Stuppia et al., 2002
Italy
20
27
32
62
12
23
72
116
56
108
Boduroglu et al., 2004
Turkey
86
58
55
30
17
3
227
146
89
36
Acacio et al., 2005
Brazil
35
54
30
25
5
9
100
133
40
43
Da Silva et al., 2005
Brazil
67
84
72
67
15
7
206
235
102
81
Coppede et al., 2006
Italey
20
39
43
54
16
18
83
132
75
90
Liang et al., 2006
China
7
16
20
34
3
20
34
66
26
74
Rai et al., 2006
India
97
124
40
39
12
2
234
287
64
43
Scala et al., 2006
Italy
31
74
39
125
24
57
101
273
87
239
Wang et al., 2007
China
28
48
52
42
20
10
108
138
92
62
Biselli et al., 2008
Brazil
29
100
35
77
8
17
93
229
71
39
4
Kohli et al., 2008
India
74
71
29
32
0
6
177
174
29
44
Martinez-Frias et al., 2008
Spain
61
76
61
85
24
27
183
237
109
139
Egypt
20
33
17
12
5
3
57
78
27
18
Santos-Reboucas et al., 2008
Brazil
51
49
43
47
9
12
145
145
61
71
Wang et al., 2008
China
14
36
32
29
18
5
60
101
68
39
Brandalize et al., 2009
Brazil
94
86
113
93
32
18
301
265
177
129
Coppede et al., 2009
Italy
25
40
52
55
17
18
102
135
86
91
September 2014 | Volume 9 | Issue 9 | e108552
Cyril et al., 2009
India
33
60
3
0
0
0
69
120
3
0
Kokotas et al., 2009
Denmark
92
445
72
449
13
90
256
1339
98
629
Pozzi et al., 2009
Italy
28
62
30
93
16
29
86
217
62
151
Coppede et al., 2010
Italy
5
11
19
17
5
4
29
39
29
25
Liao et al., 2010
China
12
23
26
33
22
12
50
79
70
57
Vranekoviz et al., 2010
Croatia
49
66
49
64
13
11
147
196
75
86
Bozovic et al., 2011
Croatia
46
101
55
97
11
23
147
299
77
143
Sadiq et al., 2011
Jordan
23
23
27
5
3
1
73
51
33
7
Tayeb, 2012
Saudi Arabia
16
22
10
14
4
4
42
58
18
22
Zampieri et al., 2012
Brazil
40
94
55
73
10
18
135
261
75
109
Kaur & Kaur, 2013
India
86
89
22
22
2
0
194
200
26
22
Pandey et al., 2013
India
67
87
12
9
2
3
146
183
16
15
Elsayed et al., 2014
Egypt
11
30
12
24
3
7
34
84
18
38
doi:10.1371/journal.pone.0108552.t002
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
Meguid et al., 2008
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
Figure 2. Forest plots (Random effect) showed significant association between MTHFR C677T polymorphism and risk of Down
syndrome using allele contrast model (C versus T). Results of individual and summary OR estimates and 95% CI of each study were shown.
Horizontal lines represented 95% CI, and dotted vertical lines represent the value of the summary OR.
doi:10.1371/journal.pone.0108552.g002
analyses were performed using the computer program MIX
version 1.7 [24]. The control genotypes were tested for HardyWeinberg equilibrium (HWE) using the Goodness of fit Chisquare test. The quality of the included studies was measured
according to the scoring system for randomized controlled
association studies proposed by Clark and Baudouin [25]. Case
control studies scoring ,5 were defined as low quality study and
those $5 were defined as high quality study.
Inclusion criteria
Included studies had to meet the following criteria: (1) article
should be published; (2) article should have sufficient data to
calculate the odds ratio with 95% CI; (3) article should be case
control association study; and (4) author should describe the
genotyping protocols.
Data extraction
The following data were extracted from each study: first
author’s name, publication year, journal name, country name,
genotyping method, and different MTHFR genotype numbers.
Publication bias
Funnel plots of precision by log (OR) and standard error by log
(OR) were plotted to determine publication bias and asymmetrical
funnel plots represent publication bias. Begg and Mazumdar rank
correlation [26] and Egger’s regression intercept [27] tests were
adopted to assess the publication bias.
Meta-analysis
Statistical analysis of maternal MTHFR C677T polymorphism
and DS risk was estimated by Odds ratio (ORs) with 95%
confidence intervals (CIs). The heterogeneity was tested by the Qstatistics with p-values ,0.05. Subgroup analysis was done to
know the source of heterogeneity. If higher heterogeneity (I2.
50%) would be observed, the random effect model [22] would be
applied. Otherwise, fixed-effect model [23] was applied to obtain
the summary OR and 95% CI. All p values were two-sided and a
p value of less than 0.05 was considered statistically significant. All
PLOS ONE | www.plosone.org
Results
Eligible Studies
With our original search criterion, 85 articles were found. After
reviewing each original article, 50 publications were excluded
including reviews, case studies, editorials etc. (Figure 1). Following
these exclusions, 34 individual case-control studies with a total of
5
September 2014 | Volume 9 | Issue 9 | e108552
PLOS ONE | www.plosone.org
Table 3. Summary estimates for the odds ratio (OR) of MTHFR C677T in various allele/genotype contrasts, the significance level (p value) of heterogeneity test (Q test), the I2
metric and publication bias p-value (Egger Test) in total studies, Asian, American and European studies.
Genetic
Contrast
All
Asian
American
6
European
Heterogeneity
p-value (Q test)
Publication Bias
(p of Egger’s test)
Fixed effect OR
(95% CI), p
Random effect OR
(95% CI), p
Allele Contrast (T vs. C)
1.22 (1.1321.31), ,0.0001
1.26 (1.0921.46), 0.001
,0.0001
69.42
0.14
Co-dominant (CT vs. CC)
1.23 (1.1121.36), ,0.0001
1.29 (1.1021.51), 0.001
0.0002
52.49
0.02
Homozygote (TT vs. CC)
1.44 (1.2221.69), ,0.0001
1.49 (1.1321.97), 0.008
,0.0001
57.3
0.56
Dominant (TT+CT vs. CC)
1.28 (1.1621.41), ,0.0001
1.35 (1.1321.60), 0.0008
,0.0001
63.56
0.05
Recessive (CT+CC vs. TT)
0.76 (0.6520.88), 0.0004
0.76 (0.6020.94), 0.01
0.0044
43.68
0.926
Allele Contrast (T vs. C)
1.53 (1.2921.82), ,0.0001
1.52 (1.0922.1), 0.01
0.0003
69.43
0.82
Co-dominant (CT vs. CC)
1.52 (1.2121.91), 0.0003
1.57 (1.1422.14), 0.005
0.09
38.05
0.11
Homozygote (TT vs. CC)
2.41 (1.6223.59), ,0.0001
2.21 (1.0324.74), 0.0411
0.0074
60.04
0.204
I2 (%)
1.64 (1.3222.0), ,0.0001
1.70 (1.1822.4), 0.004
0.01
56.67
0.30
0.54 (0.3720.78), ,0.0001
0.58 (0.2921.16), 0.12
0.0094
58.77
0.334
Allele Contrast (T vs. C)
1.23 (1.0721.39), 0.003
1.19 (0.9921.44), 0.06
0.06
47.69
0.11
Co-dominant (CT vs. CC)
1.42 (1.1721.71), 0.0002
1.42 (0.9722.06), 0.066
0.0005
73.15
0.908
Homozygote (TT vs. CC)
1.68 (1.2422.28), 0.0008
1.58 (0.8422.95), 0.148
0.0007
72.07
0.667
Dominant (TT+CT vs. CC)
1.48 (1.2421.76), ,0.0001
1.44 (0.9522.19), 0.078
,0.0001
80.11
0.782
Recessive (CT+CC vs. TT)
0.69 (0.5120.92), 0.0136
0.72 (0.4421.18), 0.203
0.0159
59.42
0.753
Allele Contrast (T vs. C)
1.03 (0.9321.15), 0.482
1.04 (0.9321.16), 0.451
0.3576
8.81
0.084
Co-dominant (CT vs. CC)
0.99 (0.8521.16), 0.956
1.00 (0.8521.17), 0.992
0.3774
6.87
0.050
Homozygote (TT vs. CC)
1.09 (0.8721.37), 0.422
1.09 (0.8521.40), 0.455
0.3715
7.45
0.329
Dominant (TT+CT vs. CC)
1.02 (0.8821.17), 0.787
1.03 (0.8721.21), 0.704
0.308
13.58
0.041
Recessive (CT+CC vs. TT)
0.90 (0.7321.10), 0.322
0.90 (0.7221.11), 0.339
0.570
0
0.948
September 2014 | Volume 9 | Issue 9 | e108552
doi:10.1371/journal.pone.0108552.t003
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
Dominant (TT+CT vs. CC)
Recessive (CT+CC vs. TT)
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
Figure 3. Forest plots (Random effect) showed significant association between MTHFR C677T polymorphism and risk of Down
syndrome. Results of individual and summary OR estimates and 95% CI of each study were shown using homozygote model (TT versus CC).
doi:10.1371/journal.pone.0108552.g003
12.14% respectively. Frequencies of CC and CT genotypes were
highest in both cases and controls (Table 2). In cases and controls,
the allele C was the most common. All five genetic models; -allele
contrast (T vs C) homozygote (TT vs CC), codominant (CT vs
CC), dominant (TT+CT vs CC) and recessive (TT vs CT+CC)
models were used to evaluate C677T polymorphism as DS risk.
3,098 cases and 4,852 controls were found to be suitable for
inclusion into meta-analysis and listed in Table 1 (Figure 1).
These studies were published between 1999 and 2013. All these
thirty four studies were performed in different countries- Brazil
[28–33], China [4,34–36], Croatia [8,37], Egypt [38,39], France
[40], India [1,5,41–43], Ireland [44], Italy [7,13,45–48], Jordan
[49], Netherlands [50], Saudi Arabia [2], Spain [51], Turkey [52]
and USA [3,6] (Table 1).
Meta-analysis
Meta-analysis with allele contrast showed significant association
between maternal 677T allele and DS with both fixed effect
(ORTvsC = 1.22; 95% CI = 1.13–1.31; p = ,0.0001) and random
effect models (ORTvsC = 1.26; 95% CI = 1.09–1.45; p = 0.001)
(Figure 2) (Table 3). In cumulative meta-analysis using random
effect model, the association of maternal T allele with DS turned
statistically significant with the addition of study of Wang et al.
(2008) and remained significant thereafter.
Table 3 summarizes the ORs with corresponding 95% CIs for
association between maternal C677T polymorphism and risk of DS
in dominant, recessive, homozygote and co-dominant models. With
our primary analysis, there was an increased risk of DS among
mutant homozygote variants (TT), with both fixed
(ORTTvs.CC = 1.44; 95% CI = 1.2221.69, p = ,0.0001) and ran-
Characteristics of included studies
In thirty four studies included in the present meta-analysis, the
smallest case sample size was 26 [39] and highest sample size was
239 [32]. ORs for more than one were reported in twenty four
articles [1,2,4–6,8,13,28–30,32,33,35–39,42,43,46–49,51,52]. Except two studies [28,43], control populations of all articles were in
Hardy-Weinberg equilibrium.
In all thirty four studies, total cases were 3,098 with CC (1,396),
CT (1,326) and TT (376), and controls were 4,852 with CC
(2,329), CT (2,015), and TT (508) genotypes. In controls
genotypes, percentage of CC, CT and TT were 48.00%,
41.53%, and 10.47% respectively. In total cases, genotype
percentage of CC, CT, and TT was 45.06%, 42.8% and
PLOS ONE | www.plosone.org
7
September 2014 | Volume 9 | Issue 9 | e108552
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
Figure 4. Forest plots (Random effect) showed significant association between MTHFR C677T polymorphism and risk of Down
syndrome using dominant model (TT+CT versus CC). Results of individual and summary OR estimates and 95% CI of each study were shown.
doi:10.1371/journal.pone.0108552.g004
p = 0.003; I2 = 47.69%; Pheterogeneity = 0.06; PPb = 0.11) (Figure 6)
no significant association was found in American and European
population (for T vs. C: OR = 1.03; 95% CI = 0.9321.15;
p = 0.482; I2 = 8.81%; Pheterogeneity = 0.357; PPb = 0.084) (Figures 7; Table 3).
dom (ORTTvs.CC = 1.49; 95% CI = 1.1321.97, p = 0.008) effect
models with moderate statistical heterogeneity between-study
(Figure 3). Association of mutant heterozygous genotype (CT vs.
CC) was observed significant with fixed (ORCTvs.CC = 1.23; 95%
CI = 1.1121.36; p = ,0.0001) and random (ORCTvs.CC = 1.29;
95% CI = 1.1021.51; p = 0.001) effect models. Similarly combined
mutant genotypes (TT+CT vs. CC) showed significant association
with DS using both fixed (ORTT+CTvs.CC = 1.28; 95% CI = 1.162
1.41; p = ,0.0001) and random (ORTT+CTvs.CC = 1.35; 95%
CI = 1.1321.60; p = 0.0008) effect models (Figure 4).
Heterogeneity and Sensitive analysis
A true heterogeneity existed between studies for allele (PheterQ = 107.92, df = 33, I2 = 69.42%, t2 = 0.12)
and mutant genotypes (Pheterogeneity = ,0.0001, Q = 74.90,
df = 32, I2 = 57.3%, t2 = 0.10) comparisons. The ‘I2’ value of more
than 50% for between studies comparison in both allele and
genotype analysis shows high level of true heterogeneity. In Asian
(Pheterogeneity = 0.0003, I2 = 67.43%) and American (Pheterogene2
ity = ,0.0001, I = 83.25%) allele contrast meta-analysis significant
high heterogeneity was observed, in European sub-group metaanalysis low heterogeneity was observed (Pheterogeneity = 0.357,
I2 = 8.81) in allele contrast model.
In allele contrast meta-analysis, sensitivity analysis performed by
exclusion of the studies in which control population was not in
Hardy Weinberg equilibrium, studies with small sample size and
studies with high p values. Control population of only two studies
ogeneity = ,0.0001,
Stratified analysis
We also performed sub-group analysis which is based on
geographic distribution of population. Out of 34 studies included
in present meta-analysis, 11 studies were from Asia, 13 from
Europe, 8 from America and 2 from Africa. The subgroup analysis
by geographical regions revealed that the significant association
between the maternal MTHFR C677T polymorphism and DS
existed in Asian population (for T vs. C: OR = 1.51; 95%
CI = 1.0922.10; p = 0.01; I2 = 69.43%; Pheterogeneity = 0.0003;
PPb = 0.82) (Figure 5; Table 3). Except allele contrast model of
American population (T vs. C: OR = 1.23; 95% CI = 1.0721.39;
PLOS ONE | www.plosone.org
8
September 2014 | Volume 9 | Issue 9 | e108552
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
Figure 5. Forest plots (Random effect) showed significant association between MTHFR C677T polymorphism and risk of Down
syndrome in Asian studies using allele contrast model (T versus C). Results of individual and summary OR estimates and 95% CI of each
study were shown.
doi:10.1371/journal.pone.0108552.g005
[28,43] were not in HW equilibrium and heterogeneity did not
decreased after exclusion of these studies (p = ,0.0001,
I2 = 70.00%). Exclusion of seven studies with small sample size,
less than 50 (O’Leary et al. [44], n = 41; Liang et al. [34], n = 30;
Mequid et al [38], n = 42; Cyril et al. [42], n = 36; Coppede et al.
[48], n = 29; Tayeb [2], n = 30; Elsayed et al. [39], n = 26), also
did not decreased heterogeneity (Pheterogeneity = ,0.0001,
I2 = 72.98%). Similarly exclusion of eleven studies with very high
p value (O’Leary et al. [44], p = 0.87; Acacio et al. [28], p = 0.40;
Scala et al. [7], p = 0.91; Martinez-Frias et al. [51], p = 0.90; Pozzi
et al. [13], p = 0.84;Vranekoviz et al. [37], p = 0.43; Bozovic et al.
[8], p = 0.58; Tayeb [2], p = 0.74; Elsayed et al. [39], p = 0.65;
Kaur and Kaur [5], p = 0.52; Pandey et al. [43], p = 0.44) did not
decrease heterogeneity but increased odds ratio (OR = 1.29, 95%
CI = 1.1821.41, p = ,0.0001).
p = 0.14 for T vs. C; Begg’s p = 0.38, Egger’s p = 0.56 for TT vs.
CC; Begg’s p = 0.13, Egger’s p = 0.05 for TT+CT vs. CC and
Begg’s p = 0.19, Egger’s p = 0.0.05 for TT vs. CC+CT) but
publication bias was observed in co-dominant model (Begg’s
p = 0.04, Egger’s p = 0.02 for CT vs. CC) of overall by using
Begg’s and Egger’s test (Table 3). Funnel plots were showed in
Figures 8 and 9.
Discussion
In 1999, James et al [3] reported that genetic polymorphism of
folate and homocysteine pathway enzymes predispose a woman to
abnormal chromosome segregation, which act as risk factor for DS
pregnancy. In subsequent years, several in vivo studies in humans
suggested that chronic folate deficiency has been associated with
abnormal DNA methylation [11,53,54], and aberrant chromosome segregation [6,55259]. Population-based studies have
shown that folic acid intake during fetal development has a
protective effect, resulting in a significant reduction in the
Publication bias
Publication bias was not observed in allele contrast, homozygote, dominant and recessive models (Begg’s p = 0.28, Egger’s
PLOS ONE | www.plosone.org
9
September 2014 | Volume 9 | Issue 9 | e108552
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
Figure 6. Forest plots (Random effect) showed no association between MTHFR C677T polymorphism and risk of Down syndrome in
American studies using allele contrast model (T versus C). Results of individual and summary OR estimates and 95% CI of each study were
shown.
doi:10.1371/journal.pone.0108552.g006
Figure 7. Forest plots (Fixed effect) showed no association between MTHFR C677T polymorphism and risk of Down syndrome in
European studies using allele contrast model (T versus C). Results of individual and summary OR estimates and 95% CI of each study were
shown. Horizontal lines represented 95% CI, and dotted vertical lines represent the value of the summary OR.
doi:10.1371/journal.pone.0108552.g007
PLOS ONE | www.plosone.org
10
September 2014 | Volume 9 | Issue 9 | e108552
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
Figure 8. Funnel plots a2f. a. Precision by log odds ratio for additive model; b. standard error by log odds ratio for additive model; c. precision by
log odds ratio for co-dominant model; d. standard error by log odds ratio for co-dominant model; e. precision by log odds ratio for dominant model;
f. standard error by log odds ratio for Dominant model.
doi:10.1371/journal.pone.0108552.g008
occurrence of developmental defects, like neural tube defects
(NTD), congenital heart defects, limb defects, and orofacial clefts
[60].
PLOS ONE | www.plosone.org
Meta-analysis is a powerful tool for analyzing cumulative data
with small and low power studies. Several meta-analyses were
published accessing MTHFR as risk factor to various diseases/
11
September 2014 | Volume 9 | Issue 9 | e108552
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
Figure 9. Funnel plots a2f. a. Precision by log odds ratio for additive model; b. standard error by log odds ratio for additive model for Asian
studies; c. precision by log odds ratio for additive model; d. standard error by log odds ratio for additive model for American studies; e. precision by
log odds ratio for additive model; f. standard error by log odds ratio for additive model for European studies.
doi:10.1371/journal.pone.0108552.g009
PLOS ONE | www.plosone.org
12
September 2014 | Volume 9 | Issue 9 | e108552
Reported
Allelic contrast
1.26 (1.09–1.46), 0.001
,0.0001
69.42
doi:10.1371/journal.pone.0108552.t004
3048
Present Study, 2014
34
PLOS ONE | www.plosone.org
disorders like- neural tube defects [61,62], cleft lip and palate [63],
stroke [64], psychiatric disorders [65]. During literature search, we
identified four meta-analyses [66–69] published between 2007 and
2013. They examined the effect of maternal MTHFR C677T as
DS risk, but no consistent conclusion was achieved. Zintzaras [66]
performed a meta-analysis based on eleven studies and did not find
any significant association between the maternal MTHFR
polymorphisms and DS risk. Medica et al. [67] aggregated sixteen
studies and reported significant relationship between the maternal
mutant genotypes (TT+CT vs CC) and risk of DS child. Recently,
Wu et al. [68] published a meta-analysis (included twenty eight
studies with 2806 cases/4597 controls), and found statistical
association with dominant model (OR = 1.305, 95% CI = 1.125–
1.514, p = 0, p = 0.003). Yang et al. [69] performed a metaanalysis which was based on twenty six studies (2458 cases/3144
controls) and found statistically significant association in allele
contrast model (OR = 1.28; 95% CI: 1.11–1.47) (Table 4). Several
newly published studies were not included in the previous
published meta-analyses. So authors conducted a comprehensive
meta-analysis with the largest number of studies (34 studies). In the
present meta-analysis significant association was found between
maternal C677T polymorphism and DS risk in total 34 studies
using all five genetic models. Whereas in stratified analysis, except
allele contrast model in American population, no significant
association was observed in European and American population
but significant higher risk was found in Asian population. Such
phenomenon probably could be ascribed to the folate metabolism
profile and dietary structure of different regions.
There are few limitations of the present meta-analysis like- i) we
used crude ORs in the pooled analysis without adjustment; ii) the
relatively small sample size in some of the included studies,
especially those from Asia; iii) we considered only one gene
polymorphism (MTHFR C677T) of folate pathway. Present metaanalysis had several advantages/strength to the previous published
meta-analyses like- (i) the publication bias was not detected in
present meta-analysis, (ii) pooled number of cases and controls
from different studies significantly increased the statistical power of
the analysis, (iii) largest number of studies (34 studies) with largest
sample size (3,098 cases and 4,852 controls) was included in the
present meta-analysis, (iv) controls included in the present metaanalysis was mothers of healthy child, (v) distribution of genotypes
in control mothers except two studies was in Hardy-Weinberg
equilibrium, (vi) significant association was found between
maternal MTHFR C677T polymorphism and DS risk in allelic
contrast, homozygote, co-dominant and dominant genetic models
and (vii) in addition we did sub-group analysis according to
geographical regions.
In conclusion, results of present meta-analysis suggest that the
maternal MTHFR 677T allele is a risk factor for development of
DS pregnancy. However the results of present meta-analysis were
based on single gene polymorphism and significant heterogeneity
was also observed; hence results should be interpreted with
caution.
4852
Reported
Reported
Allelic contrast
Dominant model
1.224 (1.085–1.38), 0.001
1.28 (1.11–1.47)
,0.01
0.0
48.0
58.2
2806
4597
2458
28
Wu et al., 2013
Yang et al., 2013
26
3144
Not reported
Not reported
Allelic contrast
Dominant model
1.40 (1.16–1.70), 0.0006
1.20 (1.06–1.35)
0.03
–
–
49
1545
2052
1129
16
Medica et al., 2009
Zintaras, 2007
11
1489
Subgroup analysis
Model
OR (95% CI), p-value
Heterogeneity p-value (Q test)
I2 (%)
Controls
Cases
Number of Studies
Study
Table 4. A comparative analysis of details of Odds Ratio, 95% CI, genetic models reported in total 5 (including present) meta-analysis published so far analyzing case-control
studies of MTHFR C677T polymorphism and Down syndrome.
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
Supporting Information
Checklist S1 PRISMA checklist.
(DOC)
Author Contributions
Conceived and designed the experiments: VR PK OPM. Performed the
experiments: UY SKY. Analyzed the data: VR UY. Contributed reagents/
materials/analysis tools: VR UY. Wrote the paper: VR.
13
September 2014 | Volume 9 | Issue 9 | e108552
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
References
28. Acácio GL, Barini R, Bertuzzo CS, Couto EC, Annichino-Bizzacchi JM, et al.
(2005) Methylenetetrahydrofolate reductase gene polymorphisms and their
association with trisomy 21. Prenat Diagn 25: 1196–1199.
29. da Silva LRJ, Vergani N, Galdieri LC, Porto MPR, Longhitano SB, et al. (2005)
Relationship between polymorphisms in genes involved in homocysteine
metabolism and maternal risk for Down syndrome in Brazil. Am J Med Genet
Part A 135A: 263–267.
30. Biselli JM, Goloni-Bertollo EM, Zampieri BL, Haddad R, Eberlin MN, et al.
(2008) Genetic polymorphisms involved in folate metabolism and elevated
plasma concentrations of homocysteine: maternal risk factors for Down
syndrome in Brazil. Genet Mol Res 7: 33–42.
31. Santos-Reboucas CB, Corre‘a JC, Bonomo A, Fintelman-Rodrigues N, Moura
KC, et al. (2008) The impact of folate pathway polymorphisms combined to
nutritional deficiency as a maternal predisposition factor for Down syndrome.
Dis Markers 25: 149–157.
32. Brandalize AP, Bandinelli E, dos Santos PA, Roisenberg I, Schüler-Faccini L
(2009) Evaluation of C677T and A1298C polymorphisms of the MTHFR gene
as maternal risk factors for Down syndrome and Congenital heart defects.
Am J Med Genet 149A (10): 2080–2087.
33. Zampieri BL, Biselli JM, Goloni-Bertollo EM, Vannucchi H, Carvalho VM, et
al. (2012) Maternal risk for Down syndrome is modulated by genes involved in
folate metabolism. Dis Markers 32(2): 73–81.
34. Liang X, Feng Z, Lan-Fang Z, Guo XX, Xiao GF, et al. (2005) Analysis of
Down syndrome screening and antenatal diagnosis of 3195 cases in the middle
period of pregnancy. China J Modern Medicine 20: 011.
35. Wang W, Xie W, Wang X (2007) The relationship between polymorphism of
gene involved in folate metabolism, homocysteine level and risk of Down
syndrome. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 24: 533–537.
36. Liao YP, Bao MS, Liu CQ, Liu H, Zhang D (2010) Folate gene polymorphism
and the risk of Down syndrome pregnancies in young Chinese women. Yi
Chuan 32(5): 461–466.
37. Vranekovic’ J, Babic’ Bozovic’ I, Starcevic’ Cizmarevic’ N, Buretic’- Tomljanovic’ A, Ristic’ S, et al. (2010) Functional inference of methylenetetrahydrofolate reductase gene polymorphisms on enzyme stability as a potential risk
factor for Down syndrome in Croatia. Dis Markers 28: 293–298.
38. Meguid NA, Dardir AA, Khass M, Hossieny LE, Ezzat A, et al. (2008) MTHFR
genetic polymorphism as a risk factor in Egyptian mothers with Down syndrome
children. Dis Markers 24: 19–26.
39. Elsayed GM, Elsayed SM, Ezz-Elarab SS (2013) Maternal MTHFR C677T
genotype and septal defects in offspring with Down syndrome: A pilot study. The
Egyptian J Med Hum Genet 15(1): 39–44.
40. Chadefaux-Vekemans B, Coude M, Muller F, Oury JF, Chabli A, et al. (2002)
Methylenetetrahydrofolate reductase polymorphism in the etiology of Down
syndrome. Pediatr Res 51: 766–767.
41. Kohli U, Arora S, Kabra M, Ramakrishnan L, Gulati S, et al. (2008) Prevalence
of MTHFR 677C.T polymorphism in north Indian mothers having babies
with Trisomy 21 Down syndrome. Downs Syndr Res Pract 12: 133–137.
42. Cyril C, Rai P, Chandra N, Gopinath PM, Satyamoorthy K (2009) MTHFR
gene variants C677T A1298C and association with Down syndrome: a case–
control study from South India. Indian J Hum Genet 15: 60–64.
43. Pandey SK, Mohanty PK, Polipalli SK, Kapoor S (2013) Genetic polymorphisms of MTHFR (677T and 1298C) and homocysteine metabolism as
maternal risk factor for Down’s syndrome patients in north indian population.
Int J Pharm Bio Sci; 4(2):(B)249–256.
44. O’Leary VB, Parle-McDermott A, Molloy AM, Kirke PN, Johnson Z, et al.
(2002) MTRR and MTHFR polymorphism: link to Down syndrome?
Am J Med Genet A 107: 151–155.
45. Stuppia L, Gatta V, Gaspari AR, Antonucci I, Morizio E, et al. (2002) C677T
mutation in the 5,10-MTHFR gene and risk of Down syndrome in Italy.
Eur J Hum Genet 10: 388–390.
46. Coppedè F, Marini G, Bargagna S, Stuppia L, Minichilli F, et al. (2006) Folate
gene polymorphisms and the risk of Down syndrome pregnancies in young
Italian women. Am J Med Genet A 140(10): 1083–1091.
47. Coppede’ F, Migheli F, Bargagna S, Siciliano G, Antonucci I, et al. (2009)
Association of maternal polymorphisms in folate metabolizing genes with
chromosome damage and risk of Down syndrome offspring. Neurosci Lett 449:
15–19.
48. Coppedè F, Grossi E, Migheli F, Migliore L (2010) Polymorphisms in folatemetabolizing genes, chromosome damage, and risk of Down syndrome in Italian
women: identification of key factors using artificial neural networks. BMC Med
Genomics 3: 42.
49. Sadiq MF, Al-Refai EA, Al-Nasser A, Khassawneh M, Al-Batayneh Q (2011)
Methylenetetrahydrofolate reductase polymorphisms C677T and A1298C as
maternal risk factors for Down syndrome in Jordan. Genet Test Mol Biomarker
15: 1–7.
50. Kokotas H, Grigoriadou M, Mikkelsen M, Giannoulia-Karantana A, Petersen
MB (2009) Investigating the impact of the Down syndrome related common
MTHFR 677C[T polymorphism in the Danish population. Dis Markers 27:
279–285.
51. Martı́nez-Frı́as ML (2008) The biochemical structure and function of
methylenetetrahydrofolate reductase provide the rationale to interpret the
1. Rai AK, Singh S, Mehta S, Kumar A, Pandey LK, et al. (2006) MTHFR C677T
and A1298C polymorphisms are risk factors for Down’s syndrome in Indian
mothers. J Hum Genet 51: 278–283.
2. Tayeb MT (2012) The methylenetetrahydrofolate reductase gene variant
(C677T) in risk mothers with Down syndrome among Saudi population.
Egyptian J Med Hum Genet 13(3): 263–268.
3. James SJ, Pogribna M, Pogribny IP, Melnyk S, Hine RJ, et al. (1999) Abnormal
folate metabolism and mutation in the methylenetetrahydrofolate reductase gene
may be maternal risk factors for Down syndrome. Am J Clin Nutr 70: 495–50.
4. Wang SS, Qiao F, Feng L, Juan-Juan LV (2008) Polymorphisms in genes
involved in folate metabolism as maternal risk factors for Down syndrome in
China. J Zhejiang Univ Sci B 9(2): 93–99.
5. Kaur A, Kaur A (2013) Prevalence of methylenetetrahydrofolate reductase 677
C-T polymorphism among mothers of Down syndrome children. Indian J Hum
Genet 19(4): 412–414.
6. Hobbs CA, Sherman SI, Yi P, Torfs CP, Hine RJ, et al. (2000) Polymorphism in
genes involved in folate metabolism as maternal risk factors for Down syndrome.
Am J Hum Genet 67: 623–630.
7. Scala I, Granese B, Sellitto M, Salome S, Sammartino A, et al. (2006) Analysis of
seven maternal polymorphisms of genes involved in homocysteine/folate
metabolism and risk of Down syndrome offspring. Genet Med 8: 409–416.
8. Božović IB, Vraneković J, Cizmarević NS, Mahulja-Stamenković V, Prpić I, et
al. (2011) MTHFR C677T and A1298C polymorphisms as a risk factor for
congenital heart defects in Down syndrome. Pediatr Int 53(4): 546–550.
9. James SJ, Melnyk S, Pogribna M, Pogribny IP, Caudill MA (2002) Elevation in
S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic
mechanism for homocysteine-related pathology. J Nutr 132(8 Suppl): 2361S–
2366S.
10. Pogribny IP, James SJ, Jernigan S, Pogribna M (2004) Genomic hypomethylation is specific for preneoplastic liver in folate/methyl deficient rats and does not
occur in non-target tissues. Mutat Res. 548(1–2): 53–59.
11. Pogribna M, Melnyk S, Pogribny I, Chango A, Yi P, et al. (2001) Homocysteine
metabolism in children with Down syndrome: in vitro modulation. Am J Hum
Genet 69: 88–95.
12. Parry EM, Parry JM, Corso C, Doherty A, Haddad F, et al. (2002) Detection
and characterization of mechanisms of action of aneugenic chemicals.
Mutagenesis. 17(6): 509–521.
13. Pozzi E, Vergani P, Dalpra’ L, Combi R, Silvestri D, et al. (2009) Maternal
polymorphisms for methyltetrahydrofolate reductase and methionine synthetase
reductase and risk of children with Down syndrome. Am J Obstet Gynecol 63:
e1–e6.
14. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, et al. (1995) A candidate
genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111–113.
15. Bagley PJ, Selhub J (1998) A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated
tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA 95(22): 13217–
13220.
16. Brattström L, Wilcken DE, Ohrvik J, Brudin L (1998) Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not
to vascular disease: the result of a meta-analysis. Circulation 98(23): 2520–2526.
17. van der Put NM, Eskes TK, Blom HJ (1997) Is the common 677CT mutation in
the methylenetetrahydrofolate reductase gene a risk factor for neural tube
defects? A meta-analysis. Q J Med 90: 111–115.
18. Blanton SH, Henry RR, Yuan Q, Mulliken JB, Stal S, et al. (2011) Folate
pathway and nonsyndromic cleft lip and palate. Birth Defects Res A Clin Mol
Teratol 91: 50–60.
19. Hua Y, Zhao H, Kong Y, Ye M (2011) Association between the MTHFR gene
and Alzheimer’s disease: a meta-analysis. Int J Neurosci 121(8): 462–71.
20. Benes P, Kankova K, Muzik J, Groch L, Benedik J et al. (2001)
Methylenetetrahydrofolate reductase polymorphism, typeII diabetes mellitus,
coronary artery disease, and essential hypertension in the Czech population.
Mol Genet Metab 73: 188–195.
21. Jönsson EG, Larsson K, Vares M, Hansen T, Wang AG, et al. (2008) Two
methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms, schizophrenia and bipolar disorder: an association study. Am J Med Genet B Neuropsychiatr Genet 147B: 976–982.
22. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Controlled
Clinical Trials. 7: 177–188.
23. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from
retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
24. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG (2006) Development and
validation of MIX: comprehensive free software for meta-analysis of causal
research data. BMC Med Res Methodol. 2006;6: 50.
25. Clark MF, Baudouin SV (2006) A systematic review of the quality of genetic
association studies in human sepsis. Intensive Care Med 32(11): 1706–1712.
26. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation
test for publication bias. Biometrics 50(4): 1088–1101.
27. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis
detected by a simple, graphical test. BMJ 315: 629–634.
PLOS ONE | www.plosone.org
14
September 2014 | Volume 9 | Issue 9 | e108552
MTHFR C677T Polymorphism as Risk Factor for Down Syndrome
52.
53.
54.
55.
56.
57.
58.
59.
60.
61. Zhang T, Lou J, Zhong R, Wu J, Zou L, et al. (2013) Genetic Variants in the
Folate Pathway and the Risk of Neural Tube Defects: A Meta-Analysis of the
Published Literature. PLos One 8: e59570.
62. Yadav U, Kumar P, Yadav SK, Mishra OP, Rai V (2014) Polymorphisms in
folate metabolism genes as maternal risk factor for Neural Tube Defects: an
updated meta-analysis. Metab Brain Dis. [Ahead of Print; DOI: 10.1007/
s11011–014–9575–7].
63. Zhao M, Ren Y, Shen L, Zhang Y, Zhou B (2014) Association between
MTHFR C677T and A1298C Polymorphisms and NSCL/P Risk in Asians: A
Meta-Analysis. Plos One 9(3): e88242.
64. Yadav S, Hasan N, Marjot T, Khan MS, Prasad K, et al. (2013) Detailed
Analysis of Gene Polymorphisms Associated with Ischemic Stroke in South
Asians. PLos One 8: e57305.
65. Peerbooms OL, van Os J, Drukker M, Kenis G, Hoogveld L, et al. (2011) Metaanalysis of MTHFR gene variants in schizophrenia, bipolar disorder and
unipolar depressive disorder: evidence for a common genetic vulnerability?
Brain Behav Immun 25(8): 1530–1543.
66. Zintzaras E (2007) Maternal gene polymorphisms involved in folate metabolism
and risk of Down syndrome offspring: a meta analysis. J Hum Genet 52: 943–
953.
67. Medica I, Maver A, Augusto GF, Peterlin B (2009) Polymorphisms in genes
involved in folate metabolism as maternal risk factors for Down syndrome- metaanalysis. Cent Eur J Med 4: 395–408.
68. Wu X, Wang X, Chan Y, Jia S, Luo Y, et al. (2013) Folate metabolism gene
polymorphisms MTHFR C677T and A1298C and risk for Down syndrome
offspring: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 167(2): 154–159.
69. Yang M, Gong T, Lin X, Qi L, Guo Y, et al. (2013) Maternal gene
polymorphisms involved in folate metabolism and the risk of having a Down
syndrome offspring: a meta-analysis. Mutagenesis 28(6): 661–671.
epidemiological results on the risk for infants with Down syndrome. Am J Med
Genet A 146A(11): 1477–1482.
Boduroğlu K, Alanay Y, Koldan B, Tunçbilek E (2004) Methylenetetrahydrofolate reductase enzyme polymorphisms as maternal risk for Down syndrome
among Turkish women. Am J Med Genet 127A: 5–10.
Balaghi M, Wagner C (1993) DNA methylation in folate deficiency: use of CpG
methylase. Biochemical and Biophysical Research Communications 193: 1184–
1190.
Fenech M (2001) The role of folic acid and Vitamin B12 in genomic stability of
human cells. Mutat Res 475: 57–67.
Libbus BL, Borman LS, Ventrone CH, Branda RF (1990) Nutritional folate
deficiency in CHO cells: chromosomal abnormalities associated with perturbations in nucleic acid precursors. Cancer Genet Cytogenet 46: 231–242.
Leyton BL, Mergudich D, del la Torre D, Sans J (1995) Impaired chromosome
segregation in plant anaphase alter moderate hypomethylation of DNA. Cell
Prolif 28: 481–496.
Pogribny IP, Basnakian AG, Miller BJ, Lopatina NG, Poirier LA, et al. (1995)
Breaks in genomic DNA and within the p53 gene are associated with
hypomethylation in livers of folate/methyl-deficient rats. Cancer Res 55(9):
1894–1901.
Chen RZ, Pettersson U, Beared C, Jackson-Grusby I, Jaenisch R (1998) DNA
hypomethylation leads to elevated mutation rates. Nature 395: 89–93.
Titenko-Holland N, Jacob RA, Shang N, Balaraman A, Smith MT (1998)
Micronuclei in lymphocytes and exfoliated buccal cells of postmenopausal
women with dietary changes in folate. Mutat Res 417: 101–114.
Botto LD, Yang Q (2000) 5, 10-methylenetetrahydrofolate reductase variants
and congenital anomalies: A huge review. Am J Epidemiol 151: 862–877.
PLOS ONE | www.plosone.org
15
September 2014 | Volume 9 | Issue 9 | e108552